← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyStandard DatabasestalePhase 2
Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)
Shanghai Kechow Pharma, Inc.·PD-1
2 trials·t½ 53 h
Overview
Program
Tunlametinib+PD-1 mAb
Overview
Company
Shanghai Kechow Pharma, Inc.
Overview
Modality
ANTIBODY
Overview
Target
PD-1
Overview
Indication
Gastric Adenocarcinoma
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
PK/PD
Half-life
53 h
Toxicology
Major finding
From discovery to therapeutic development of monoclonal antibodies.. Monoclonal antibodies (mAbs) represent a powerful targeted therapeutic arsenal for treating diverse diseases, ranging from infectious and chronic conditions to cancer. However, successful development requires overcoming several complex stability and solubility challenges in the final stages. This review examines the discovery, ch…
Clinical
Safety signal
From discovery to therapeutic development of monoclonal antibodies.. Monoclonal antibodies (mAbs) represent a powerful targeted therapeutic arsenal for treating diverse diseases, ranging from infectious and chronic conditions to cancer. However, successful development requires overcoming several complex stability and solubility challenges in the final stages. This review examines the discovery, ch…
Clinical
Program phase
PHASE_2